menu
    • menu
    [{"orgOrder":0,"company":"Xiamen Biotime Biotechnology","sponsor":"Adlai Nortye","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"AN4005","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Xiamen Biotime Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xiamen Biotime Biotechnology \/ Adlai Nortye Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Xiamen Biotime Biotechnology \/ Adlai Nortye Ltd."}]

    Find Clinical Drug Pipeline Developments & Deals by Xiamen Biotime Biotechnology

    Menu

    Xiamen Biotime Biotechnology

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Xiamen Biotime Biotechnology

                            China arrow
                            Cosmoprof
                            Not Confirmed

                            Xiamen Biotime Biotechnology

                            China arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AN4005

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Adlai Nortye

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Adlai Nortye Announces Global License-out Agreement with Biotime for Several Products Including PD-L1 Inhibito...

                            Details : This includes the rights and interests of Adlai Nortye in the development, manufacturing and commercialization of AN4005 and AN3025 in Greater China, and AN1005, AN6015 and AN9015 worldwide.

                            Brand Name : AN4005

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 26, 2022

                            Lead Product(s) : AN4005

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Adlai Nortye

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth